CSIMarket
 
Gain Therapeutics Inc   (NASDAQ: GANX)
Other Ticker:  
 
 
Price: $2.5100 $-0.10 -3.831%
Day's High: $2.6 Week Perf: 13.57 %
Day's Low: $ 2.40 30 Day Perf: 2.87 %
Volume (M): 201 52 Wk High: $ 5.30
Volume (M$): $ 504 52 Wk Avg: $2.31
Open: $2.60 52 Wk Low: $0.89



 Market Capitalization (Millions $) 67
 Shares Outstanding (Millions) 27
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Gain Therapeutics Inc
Gain Therapeutics Inc. is a biotechnology company that focuses on developing small molecule therapeutics to treat rare genetic diseases and neurodegenerative disorders. The company specializes in developing drugs that target misfolded proteins, which are a common cause of these diseases. Gain Therapeutics utilizes proprietary technology platforms and computational algorithms to identify potential drug candidates and design molecules that can stabilize or restore the function of the misfolded proteins. By addressing the root cause of the diseases, the company aims to provide breakthrough treatments that can significantly improve the lives of patients. Gain Therapeutics is headquartered in Spain and Switzerland, and collaborates with leading academic institutions and research organizations to advance its drug development programs.


   Company Address: 4800 Montgomery Lane Bethesda 20814 MD
   Company Phone Number: 500-1556   Stock Exchange / Ticker: NASDAQ GANX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD        0.8% 
ALKS   -0.22%    
BMRN        1% 
ITCI        0.17% 
LLY        2.45% 
SUPN   -5.18%    
• View Complete Report
   



Management Changes

Gain Therapeutics Appoints Gene Mack as CEO Amid Phase 1b Clinical Trial for Parkinsons Treatment and Financial Challenges

Published Tue, Jan 7 2025 12:01 PM UTC

Gain Therapeutics Inc., an innovative biotechnology firm focused on developing therapies for neurodegenerative diseases, has announced the appointment of Gene Mack as its new Chief Executive Officer (CEO) and Director. Mack has been with the company since April 2024, serving as Chief Financial Officer (CFO) before stepping in as the interim CEO in June 2024. His extensive ex...

Clinical Study

Gain Therapeutics Launches Phase 1b Clinical Trial for GT-02287, Targeting GBA1 and Idiopathic Parkinsons Disease ...

Published Mon, Dec 23 2024 12:31 PM UTC

Gain Therapeutics, a pioneering biotechnology firm focused on advancing treatments for neurodegenerative disorders, recently announced the initiation of a Phase 1b clinical trial for its lead candidate, GT-02287. This ambitious study aims to assess the safety, tolerability, and preliminary efficacy of GT-02287 in individuals suffering from GBA1 (Glucocerebrosidase gene mutat...

Clinical Study

Innovative Preclinical Data GT-02287 Shows Promise in Targeting GBA1 and Idiopathic Parkinsons Disease Models

Published Mon, Oct 7 2024 11:00 AM UTC

Groundbreaking Advances in Neurological Therapies At the forefront of neurological research, Gain Therapeutics has unveiled compelling preclinical data on their novel compound, GT-02287, at the highly regarded Neuroscience 2024 conference. This pivotal research highlights the drug s significant potential in modifying disease progression in models of both GBA1 (Glucocerebros...

Clinical Study

Innovative Advances in Parkinson?s Disease Treatment Gain Therapeutics to Present Phase 1 Study Results for GT-02287

Published Thu, Sep 26 2024 11:00 AM UTC

Abstract: Gain Therapeutics is set to host a virtual webinar that will address the critical results from its Phase 1 clinical study of GT-02287, a small molecule therapy designed to target glucocerebrosidase (GCase) activity to improve outcomes in patients with Parkinson s disease. The webinar is anticipated to emphasize the positive responses gathered during the Internation...

Clinical Study

Gain Therapeutics Unveils Promising Data on GT-02287 for Parkinsons Disease Ahead of Prestigious Neuroscience 2024 C...

Published Thu, Sep 19 2024 11:00 AM UTC

In an exciting advancement for Parkinson?s disease treatment, Gain Therapeutics, Inc. (Nasdaq: GANX) has announced the presentation of groundbreaking preclinical data for its lead drug candidate, GT-02287. These findings will be showcased at the upcoming Neuroscience 2024 conference, taking place from October 5-9 in Chicago, Illinois. Notably, the company will present two la...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com